Overview

A Single and Multiple Dose Study of Lemborexant in Healthy Chinese Participants

Status:
Completed
Trial end date:
2021-01-13
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the pharmacokinetics (PK) of lemborexant and metabolites (M4, M9, and M10) in plasma in healthy Chinese participants following single and multiple oral doses of lemborexant.
Phase:
Phase 1
Details
Lead Sponsor:
Eisai Co., Ltd.
Treatments:
Lemborexant